Abstract
Objective To analyze the impact of excision repair cross complementation group 1 (ERCC1), thymidylate synthetase (TYMS) mRNA expression, and uridine-diphosphoglucuronosyl transferase 1A1 (UGT1A1)*28/*6 gene polymorphisms on chemoresponse and clinical outcome of patients with colorectal cancer treated with fluorouracil combined with oxaliplatin (FOLFOX) or fluorouracil combined with irinotecan (FOLFIRI) regimen. Methods Among the 96 patients with gastric cancer, 47 patients were treated with FOLFOX regimen, and 49 patients underwent neoadjuvant chemotherapy with FOLFIRI regimen. The gene expression of gastric cancer patients was analyzed, and the chemotherapy efficacy and prognosis of the two groups were observed. Results Chemotherapy remission rate (72.4%, 57.9%) in patients with low expression of ERCC1 and TYMS, median disease progression time (12.6, 16.9 months), median overall survival time (26.4, 23.8 months, respectively) were significantly better than those in patients with high expression of ERCC1 and TYMS (38.9%, 34.5%) and median disease progression. Time (7.9, 12.3 months respectively) and median total survival (15.7, 16.2 months respectively) were significantly different (P 0.05). In addition, there was no significant difference in the efficacy of chemotherapy between *28 and *6 genotypes (P>0.05). Conclusion The gene expression of gastric cancer patients was analyzed, and the chemotherapy efficacy and prognosis of the two groups were observed. Key words: Colorectal cancer; Excision repair cross complementing 1; Thymidylate synthetase; Uridine-diphosphoglucuronosyl transferase 1A1; Chemoresistence
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
